All In Biotech

Drug Trial Radar · NCT07472790

A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma

A Single-arm Clinical Study on the Efficacy and Safety of the Novel Oncolytic Virus Ad-TD-nsIL12 Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jul 31, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma

Conditions

  • High-grade Glioma

Interventions

  • Novel oncolytic virus Ad-TD-nsIL12(BioTTT001)Biological

    Inject Ad-TD-nsIL12 into the tumor via Ommaya reservoir, administering on days 1, 4, and 7, and infuse a PD-1 inhibitor on day 9.Ad-TD-nsIL12 is injected every 21 days (± 3 days) as appropriate in subsequent cycles. On the 7th day (±3 days) after oncolytic virus administration each cycle, a PD-1 inhibitor is given, or until disease progression or the occurrence of intolerable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the efficacy of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in treating recurrent HGG patientsTime frame: Until death,12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanbo Brain Hospital, Capital Medical University

    Beijing, Chaoyang District, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.